Picture of Vivesto AB logo

VIVE Vivesto AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Oasmia Pharmaceutical: Phase 1B Trial Of Docetaxel Micellar Is Granted Ethical Committee Approval

April 21 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * PHASE 1B TRIAL OF OASMIA’S DOCETAXEL MICELLAR IN ADVANCED
PROSTATE CANCER IS GRANTED ETHICAL COMMITTEE APPROVAL AND CAN BE
INITIATED
    * TRIAL INITIATION IS EXPECTED TO COMMENCE IN FIRST HALF OF
2021

Source text for Eikon:  ID:nMFN5wB56T 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Vivesto AB

See all news